# Cellular Immunotherapy for Viral Induced Cancer - EBV Positive Lymphomas

> **NCT02763254** · PHASE2 · TERMINATED · sponsor: **Cell Medica Ltd** · enrollment: 1 (actual)

## Conditions studied

- Hodgkin Lymphoma
- Lymphoma, Large B-Cell, Diffuse
- Post-transplant Lymphoproliferative Disorder

## Interventions

- **BIOLOGICAL:** baltaleucel-T

## Key facts

- **NCT ID:** NCT02763254
- **Lead sponsor:** Cell Medica Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-11
- **Primary completion:** 2018-02-17
- **Final completion:** 2018-02-17
- **Target enrollment:** 1 (ACTUAL)
- **Why stopped:** Insufficient recruitment rate
- **Last updated:** 2019-03-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02763254

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02763254, "Cellular Immunotherapy for Viral Induced Cancer - EBV Positive Lymphomas". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02763254. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*